• search
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

No Emergency Use Approval to Covaxin in US

|
Google Oneindia News

New Delhi, June 11: Bharat Biotech's partner for Covaxin the US has said it will no longer seek emergency use authorisation for its COVID-19 vaccine candidate. It said that it would file for a full approval of the shot after the FDA asked for additional information and data.

Ocugen which has partnered with Bharat Biotech to produce Covaxin for the US market said that the decision was based on a recommendation from the country's regulator.

No Emergency Use Approval to Covaxin in US

"The FDA provided feedback to Ocugen regarding the Master File submitted previously and recommended that we pursue a BLA submission instead of an EUA application for the vaccine candidate and requested additional information and data," Ocugen said in a statement to the New York Stock Exchange.

The company will no longer pursue an Emergency Use Authorization (EUA) for Covaxin. The FDA provided feedback to Ocugen regarding the Master File. The company had previously submitted and recommended that Ocugen pursue a BLA submission instead of an EUA application for its vaccine candidate and requested additional information and data," Ocugen said.

Ocugen is in discussions with the FDA to understand the additional information required to support a BLA submission.

The company anticipates that data from an additional clinical trial will be required to support the submission.

"Although we were close to finalising our EUA application for submission, we received a recommendation from the FDA to pursue a BLA path. While this will extend our timelines, we are committed to bringing Covaxin to the US," Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer and co-founder of Ocugen said.

"This differentiated vaccine is a critical tool to include in our national arsenal given its potential to address the SARS-CoV-2 variants, including the delta variant, and given the unknowns about what will be needed to protect US population in the long term," he added.

Reacting to the FDA''s "recommendation", Bharat Biotech said with good herd immunity and significant percentage of the population vaccinated, the pandemic is reducing in the United States, the US regulator had earlier communicated that no new EUAs will be approved for COVID-19 vaccines.

"All applications have to follow the biological license application process, which is the standard process for vaccines. Data from an additional clinical trial will be required to support the marketing application submission for Covaxin," the vaccine maker said.

No vaccine manufactured or developed from India has ever received EUA or full licensure from USFDA.
When approved, it will be a "great leap forward" for vaccines'' innovation and manufacturing from India, Bharat Biotech added.

Ocugen recently announced that it secured exclusive rights to commercialise Covaxin in Canada and has initiated discussions with Health Canada for regulatory approval.

The company will pursue expedited authorisation for the vaccine under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 in Canada.

For Daily Alerts
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
X